K Melissa Hallow
Overview
Explore the profile of K Melissa Hallow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hallow K, Greasley P, Heerspink H, Yu H
Front Pharmacol
. 2024 Dec;
15:1332388.
PMID: 39664514
Introduction: Endothelin-1 (ET-1) regulates renal and vascular function, but the clinical utility of selective ET receptor antagonists has been limited due to associated fluid retention. The mechanisms underlying fluid retention...
2.
Yu H, Greasley P, Lambers Heerspink H, Ambery P, Ahlstrom C, Hamren B, et al.
Br J Pharmacol
. 2024 Aug;
181(22):4693-4707.
PMID: 39159936
Background And Purpose: Endothelin-1 (ET-1) receptor A (ETA) antagonists reduce proteinuria and prevent renal outcomes in chronic kidney disease (CKD) patients, but their utility has been limited because of associated...
3.
Yu H, Greasley P, Lambers-Heerspink H, Boulton D, Hamren B, Hallow K
Front Pharmacol
. 2024 Apr;
15:1332394.
PMID: 38645552
Endothelin-1 (ET-1) is a potent vasoconstrictor with strong anti-natriuretic and anti-diuretic effects. While many experimental studies have elucidated the mechanisms of ET-1 through its two receptors, ET and ET, the...
4.
Basu S, Yu H, Murrow J, Hallow K
PLoS Comput Biol
. 2023 Nov;
19(11):e1011598.
PMID: 37956217
In contrast to heart failure (HF) with reduced ejection fraction (HFrEF), effective interventions for HF with preserved ejection fraction (HFpEF) have proven elusive, in part because it is a heterogeneous...
5.
Maddah E, Hallow K
J Pharmacokinet Pharmacodyn
. 2022 Jul;
49(4):471-486.
PMID: 35776281
Plasma potassium regulation within a narrow range is vital for life. The risk for hyperkalemia increases when kidney function is impaired and with therapeutic interventions such as mineralocorticoid receptor antagonists...
6.
Yu H, Basu S, Tang W, Penland R, Greasley P, Oscarsson J, et al.
J Clin Pharmacol
. 2021 Oct;
62(4):541-554.
PMID: 34657303
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to reduce the risk of worsening heart failure (HF) in subjects with HF and a reduced ejection fraction (HFrEF) in multiple clinical trials....
7.
Hallow K, Van Brackle C, Anjum S, Ermakov S
Front Physiol
. 2021 Jul;
12:679930.
PMID: 34220545
Cardiac and renal function are inextricably connected through both hemodynamic and neurohormonal mechanisms, and the interaction between these organ systems plays an important role in adaptive and pathophysiologic remodeling of...
8.
Yu H, Tang W, Greasley P, Penland R, Boulton D, Hallow K
J Clin Pharmacol
. 2020 Oct;
61(5):636-648.
PMID: 33091173
The Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study demonstrated that dapagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), reduced heart failure hospitalization and cardiovascular death in patients with...
9.
Yu H, Basu S, Hallow K
PLoS Comput Biol
. 2020 Aug;
16(8):e1008074.
PMID: 32804929
Congestive heart failure is characterized by suppressed cardiac output and arterial filling pressure, leading to renal retention of salt and water, contributing to further volume overload. Mathematical modeling provides a...
10.
Hallow K, Boulton D, Penland R, Helmlinger G, Nieves E, van Raalte D, et al.
J Pharmacol Exp Ther
. 2020 Aug;
375(1):76-91.
PMID: 32764153
Sodium glucose cotransporter 2 inhibitors (SGLT2i) reduce cardiovascular events and onset and progression of renal disease by mechanisms that remain incompletely understood but may include clearance of interstitial congestion and...